Honest Company Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Honest Company Inc trades at $5.03 (market cap $543.40M), while Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 16.3× Honest Company Inc's market cap, and Honest Company Inc is more actively traded (1,509,522 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| HNST | KYMR | |
|---|---|---|
Market Cap | $543.40M | $8.88B |
Volume | 1,509,522 | 1,028,790 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $127.31 |
52-Week Low | $2.10 | $55.80 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $447.00M | $8.27B |
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.19, up 0.58% today, with a neutral technical signal and mixed earnings performance. The company shows improving cash flow trends with $14.15M net cash flow in 2025, though revenue declined to $371.32M with a net loss of $15.69M. Recent Q2 2026 earnings beat expectations with $0.04 EPS, while strategic exits continue to reshape the business.
The stock presents a turnaround story with improving profitability metrics but faces execution risks amid revenue pressure. Analyst consensus is mixed with a $5.30 price target, representing modest upside potential. Key risks include sustained profitability challenges and competitive pressures in the personal care sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →